Hansa Biopharma AB (publ) (HNSA.ST)
SEK 29.58
(10.7%)
SEK 29.58
(10.7%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 134.7 Million SEK | 119.11% |
| 2022 | -705.08 Million SEK | -14.47% |
| 2021 | -615.96 Million SEK | 45.7% |
| 2020 | -1.13 Billion SEK | -558.58% |
| 2019 | -172.23 Million SEK | 60.75% |
| 2018 | -438.86 Million SEK | 24.42% |
| 2017 | -580.67 Million SEK | -171.93% |
| 2016 | -213.54 Million SEK | -21.61% |
| 2015 | -175.59 Million SEK | -1652.07% |
| 2014 | -10.02 Million SEK | -2439.51% |
| 2013 | 428.38 Thousand SEK | 102.26% |
| 2012 | -18.96 Million SEK | -1539.81% |
| 2011 | -1.15 Million SEK | -421.78% |
| 2010 | -221.66 Thousand SEK | -103.0% |
| 2009 | 7.38 Million SEK | 224.88% |
| 2008 | -5.91 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 405.65 Million SEK | 201.14% |
| 2024 Q2 | 269.48 Million SEK | -33.57% |
| 2024 Q3 | 389.4 Million SEK | 50.53% |
| 2023 FY | 134.7 Million SEK | 119.11% |
| 2023 Q4 | 134.7 Million SEK | 522.5% |
| 2023 Q2 | -236.66 Million SEK | 48.82% |
| 2023 Q1 | -462.41 Million SEK | 34.42% |
| 2023 Q3 | 21.64 Million SEK | 109.14% |
| 2022 FY | -705.08 Million SEK | -14.47% |
| 2022 Q3 | -424.26 Million SEK | 12.57% |
| 2022 Q1 | -485.46 Million SEK | 21.19% |
| 2022 Q2 | -485.26 Million SEK | 0.04% |
| 2022 Q4 | -705.08 Million SEK | -66.19% |
| 2021 Q1 | -1.01 Billion SEK | 10.71% |
| 2021 FY | -615.96 Million SEK | 45.7% |
| 2021 Q3 | -748.44 Million SEK | 14.94% |
| 2021 Q4 | -615.96 Million SEK | 17.7% |
| 2021 Q2 | -879.87 Million SEK | 13.13% |
| 2020 Q4 | -1.13 Billion SEK | 7.93% |
| 2020 Q3 | -1.23 Billion SEK | -773.87% |
| 2020 FY | -1.13 Billion SEK | -558.58% |
| 2020 Q1 | -140.59 Million SEK | 18.37% |
| 2020 Q2 | -140.97 Million SEK | -0.27% |
| 2019 Q2 | -308.3 Million SEK | 5.05% |
| 2019 Q4 | -172.23 Million SEK | 21.59% |
| 2019 Q3 | -219.66 Million SEK | 28.75% |
| 2019 Q1 | -324.7 Million SEK | 26.01% |
| 2019 FY | -172.23 Million SEK | 60.75% |
| 2018 Q1 | -99.44 Million SEK | 82.88% |
| 2018 Q2 | -59.43 Million SEK | 40.23% |
| 2018 Q4 | -438.86 Million SEK | -729.88% |
| 2018 Q3 | -52.88 Million SEK | 11.03% |
| 2018 FY | -438.86 Million SEK | 24.42% |
| 2017 Q4 | -580.67 Million SEK | -2194.8% |
| 2017 Q1 | -117.75 Million SEK | 44.85% |
| 2017 Q3 | -25.3 Million SEK | 60.72% |
| 2017 Q2 | -64.42 Million SEK | 45.29% |
| 2017 FY | -580.67 Million SEK | -171.93% |
| 2016 Q3 | -53.37 Million SEK | -58.44% |
| 2016 Q4 | -213.54 Million SEK | -300.08% |
| 2016 Q2 | -33.68 Million SEK | 42.02% |
| 2016 FY | -213.54 Million SEK | -21.61% |
| 2016 Q1 | -58.1 Million SEK | 66.91% |
| 2015 Q4 | -175.59 Million SEK | 8.82% |
| 2015 Q3 | -192.58 Million SEK | 7.88% |
| 2015 Q2 | -209.06 Million SEK | -10561.35% |
| 2015 Q1 | -1.96 Million SEK | 80.43% |
| 2015 FY | -175.59 Million SEK | -1652.07% |
| 2014 Q1 | 90 Thousand SEK | -78.99% |
| 2014 Q2 | -25.21 Million SEK | -28118.09% |
| 2014 Q4 | -10.02 Million SEK | 0.0% |
| 2014 FY | -10.02 Million SEK | -2439.51% |
| 2013 Q1 | -9.13 Million SEK | 51.81% |
| 2013 FY | 428.38 Thousand SEK | 102.26% |
| 2013 Q4 | 428.38 Thousand SEK | -23.5% |
| 2013 Q3 | 560 Thousand SEK | 106.13% |
| 2013 Q2 | -9.13 Million SEK | 0.0% |
| 2012 Q2 | -27.82 Million SEK | 0.0% |
| 2012 FY | -18.96 Million SEK | -1539.81% |
| 2012 Q4 | -18.96 Million SEK | 0.0% |
| 2011 FY | -1.15 Million SEK | -421.78% |
| 2011 Q4 | -1.15 Million SEK | 0.0% |
| 2011 Q2 | -12.22 Million SEK | 0.0% |
| 2010 Q2 | -9.45 Million SEK | 0.0% |
| 2010 FY | -221.66 Thousand SEK | -103.0% |
| 2010 Q4 | -221.66 Thousand SEK | 0.0% |
| 2009 Q2 | -94.7 Thousand SEK | 0.0% |
| 2009 Q4 | 7.38 Million SEK | 0.0% |
| 2009 FY | 7.38 Million SEK | 224.88% |
| 2008 Q4 | -5.91 Million SEK | 0.0% |
| 2008 FY | -5.91 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Active Biotech AB (publ) | -33.2 Million SEK | 505.747% |
| Biovica International AB (publ) | -58.73 Million SEK | 329.341% |
| Cantargia AB (publ) | -139.74 Million SEK | 196.394% |
| CombiGene AB (publ) | -101.44 Million SEK | 232.796% |
| Cyxone AB (publ) | -16.67 Million SEK | 908.086% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 4632.571% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 558.456% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 341.041% |
| Fluicell AB (publ) | -2.76 Million SEK | 4975.425% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 140.937% |
| Mendus AB (publ) | -96.29 Million SEK | 239.892% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 197.51% |
| I-Tech AB | -83.26 Million SEK | 261.788% |
| Intervacc AB (publ) | -88.16 Million SEK | 252.799% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 521.925% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | -153.101% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 806.758% |
| OncoZenge AB (publ) | -12.62 Million SEK | 1166.825% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 369.772% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 18.888% |
| Lipum AB (publ) | -8.46 Million SEK | 1691.353% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 369.303% |
| Ziccum AB (publ) | -2.13 Million SEK | 6403.603% |
| BioArctic AB (publ) | -606.58 Million SEK | 122.207% |
| Genovis AB (publ.) | -43.94 Million SEK | 406.566% |
| Camurus AB (publ) | -1.16 Billion SEK | 111.56% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 260.859% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 442.055% |
| Aptahem AB (publ) | 2.9 Million SEK | -4531.302% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 140.378% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 204.026% |
| Kancera AB (publ) | -45.69 Million SEK | 394.817% |
| Saniona AB (publ) | 40.44 Million SEK | -233.048% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 397.915% |
| AcouSort AB (publ) | -23.98 Million SEK | 661.611% |
| Xintela AB (publ) | -7.8 Million SEK | 1825.035% |
| Abliva AB (publ) | -57.24 Million SEK | 335.339% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 263.874% |
| Amniotics AB (publ) | -5.63 Million SEK | 2491.832% |
| 2cureX AB (publ) | -13.4 Million SEK | 1105.059% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | 6333.596% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | -2394.593% |
| Biosergen AB | -1.88 Million SEK | 7253.903% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | -556.792% |
| Corline Biomedical AB | -17.01 Million SEK | 891.841% |
| NextCell Pharma AB | -46.79 Million SEK | 387.895% |
| Nanologica AB (publ) | -9.38 Million SEK | 1534.896% |
| LIDDS AB (publ) | -13.51 Million SEK | 1096.951% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 169.187% |
| BioInvent International AB (publ) | -236.3 Million SEK | 157.006% |
| SynAct Pharma AB | -61.75 Million SEK | 318.122% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 729.036% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 1118.264% |
| Alzinova AB (publ) | -21.22 Million SEK | 734.637% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 747.853% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 301.297% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 2700.079% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 260.863% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | 14694.583% |
| Simris Alg AB (publ) | 85.07 Million SEK | -58.34% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 264.106% |